Following the Asia's 50 Best Bars 2025 ceremony in Macau, Campari extends heartfelt congratulations to every bar recognised ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and ...

The FDA has approved Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

Teva (TEVA) stock in focus as the FDA expands label for its migraine therapy Ajovy for children and adolescents aged 6–17 years. Read more here.

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

Parsippany: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced that the U.S. Food ...

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...